

## DAFTAR PUSTAKA

- Al Qahtany, F.H.M., Al Shali, H.A., Bayamin, A.A., 2018. Atherosclerosis : Pathophysiology and Management. *Egypt. J. Hosp. Med.* 70: 82–87. doi:10.12816/0042966
- Arso, I.A., Ambari, A.M., Hartopo, A.B., Santoso, A., 2022. Panduan Pencegahan Penyakit Kardiovaskular Aterosklerosis. Jakarta.
- Ayoub, M., 2022. Pathogenesis of Atherosclerosis: Review. *J. Pharm. Res. Int.* 54–62. doi:10.9734/jpri/2022/v34i44A36334
- Banecki, K.M.R.M., Dora, K.A., 2023. Endothelin-1 in Health and Disease. *Int. J. Mol. Sci.* 24: 11295. doi:10.3390/ijms241411295
- Barton, M., Yanagisawa, M., 2019. Endothelin: 30 Years From Discovery to Therapy. *Hypertension* 74: 1232–1265. doi:10.1161/HYPERTENSIONAHA.119.12105
- Battistelli, S., Billi, M., Manasse, G., Vittoria, A., Roviello, F., *et al.*, 1999. Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. *Angiology* 50: 629–638. doi:10.1177/000331979905000803
- Björkegren, J.L.M., Lusis, A.J., 2022. Atherosclerosis: Recent developments. *Cell* 185: 1630–1645. doi:10.1016/j.cell.2022.04.004
- Bohm, F., Pernow, J., 2007. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. *Cardiovasc. Res.* 76: 8–18. doi:10.1016/j.cardiores.2007.06.004
- BOHM, F., PERNOW, J., 2007. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. *Cardiovasc. Res.* 76: 8–18. doi:10.1016/j.cardiores.2007.06.004
- Braun, M.M., Stevens, W.A., Barstow, C.H., 2018. Stable Coronary Artery Disease: Treatment. *Am. Fam. Physician* 97: 376–384.
- Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J., Idris, I., 2009. Is diabetes a coronary risk equivalent? Systematic review and meta- analysis. *Diabet. Med.* 26: 142–148. doi:10.1111/j.1464-5491.2008.02640.x
- Cerrato, E., Forno, D., Ferro, S., Chinaglia, A., 2017. Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters. *J. Cardiovasc. Med.* 18: 567–571. doi:10.2459/JCM.0000000000000527
- Chen, P.-S., Lee, M., Tang, S.-C., Huang, P.-H., Yeh, H.-I., Jia-Yin Hou, C., Hsieh, I.-C., Lee, J.-T., Jeng, J.-S., Li, Y.-H., 2022. 2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke. *J. Formos. Med. Assoc.* 121: 1363–1370. doi:10.1016/j.jfma.2022.03.001
- Chirinos, J.A., Segers, P., Hughes, T., Townsend, R., 2019. Large-Artery Stiffness in Health and Disease. *J. Am. Coll. Cardiol.* 74: 1237–1263. doi:10.1016/j.jacc.2019.07.012
- Davidson, M.H., 2012. Cardiovascular Risk Factors in a Patient with Diabetes

- Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. *Am. J. Cardiol.* 110: 43B-49B. doi:10.1016/j.amjcard.2012.08.033
- Dzau, V.J., Balatbat, C.A., 2019. Future of Hypertension. *Hypertension* 74: 450–457. doi:10.1161/HYPERTENSIONAHA.119.13437
- Fitchett, D.H., Theroux, P., Brophy, J.M., Cantor, W.J., Cox, J.L., Gupta, M., Kertland, H., Mehta, S.R., Welsh, R.C., Goodman, S.G., 2011. Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. *Can. J. Cardiol.* 27: S402–S412. doi:10.1016/j.cjca.2011.08.107
- Ford, T.J., Corcoran, D., Berry, C., 2018. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. *Heart* 104: 284–292. doi:10.1136/heartjnl-2017-311446
- Fuchs, F.D., Whelton, P.K., 2020. High Blood Pressure and Cardiovascular Disease. *Hypertension* 75: 285–292. doi:10.1161/HYPERTENSIONAHA.119.14240
- Galley, H.F., Webster, N.R., 2004. Physiology of the endothelium. *Br. J. Anaesth.* 93: 105–113. doi:10.1093/bja/aeh163
- Gleissner, C.A., Leitinger, N., Ley, K., 2007. Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis. *Hypertension* 50: 276–283. doi:10.1161/HYPERTENSIONAHA.107.089854
- Hansson, G.K., 2005. Inflammation, Atherosclerosis, and Coronary Artery Disease. *N. Engl. J. Med.* 352: 1685–1695. doi:10.1056/NEJMra043430
- He, W.B., Ko, H.T.K., Curtis, A.J., Zoungas, S., Woods, R.L., Tonkin, A., Neumann, J.T., Turner, S.L., Hopper, I., 2023. The Effects of Statins on Cardiovascular and Inflammatory Biomarkers in Primary Prevention: A Systematic Review and Meta-Analysis. *Hear. Lung Circ.* 32: 938–948. doi:10.1016/j.hlc.2023.04.300
- Higashi, Y., Noma, K., Yoshizumi, M., Kihara, Y., 2009. Endothelial Function and Oxidative Stress in Cardiovascular Diseases. *Circ. J.* 73: 411–418. doi:10.1253/circj.CJ-08-1102
- Hussain, S., AlRashed, M., Rajan, R., Al-Jarallah, M., Brady, P.A., Soman, B., Dashti, R., 2021. Chronic Coronary Syndrome. *Ann. Clin. Cardiol.* 3: 3–7. doi:10.4103/ACCJ.ACCJ\_21\_20
- Hynynen, M., Khalil, R., 2006. The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries. *Recent Pat. Cardiovasc. Drug Discov.* 1: 95–108. doi:10.2174/157489006775244263
- Jankowich, M., Choudhary, G., 2020. Endothelin-1 levels and cardiovascular events. *Trends Cardiovasc. Med.* 30: 1–8. doi:10.1016/j.tcm.2019.01.007
- Jebari-Benslaiman, S., Galicia-García, U., Larrea-Sebal, A., Olaetxea, J.R., Alloza, I., Vandenbroeck, K., Benito-Vicente, A., Martín, C., 2022. Pathophysiology of Atherosclerosis. *Int. J. Mol. Sci.* 23: 3346. doi:10.3390/ijms23063346
- Jia, E., Liang, J., Yang, Z., Zhu, T., Wang, L., Chen, B., Cao, K., Huang, J., Ma, W., 2009. SMOKING AND CORONARY ATHEROSCLEROSIS: FOLLOW- UP STUDY IN CHINA. *Clin. Exp. Pharmacol. Physiol.* 36: 690–

695. doi:10.1111/j.1440-1681.2008.05134.x
- Kannel, W.B., 1985. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. *Am. Heart J.* 110: 1100–1107. doi:10.1016/0002-8703(85)90224-8
- Khan, M.A., Hashim, M.J., Mustafa, H., Baniyas, M.Y., Al Suwaidi, S.K.B.M., AlKatheeri, R., Alblooshi, F.M.K., Almatrooshi, M.E.A.H., Alzaabi, M.E.H., Al Darmaki, R.S., Lootah, S.N.A.H., 2020. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. *Cureus*. doi:10.7759/cureus.9349
- Knuuti, J., *et al.*, 2020. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur. Heart J.* 41: 407–477. doi:10.1093/eurheartj/ehz425
- Kulasingam, A., Pareek, M., Gragnano, F., Würtz, M., Pryds, K., Calabrò, P., Grove, E.L., 2024. Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives. *Cardiology* 149: 502–512. doi:10.1159/000537706
- Law, M.R., Morris, J.K., Wald, N.J., 2009. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 338: b1665–b1665. doi:10.1136/bmj.b1665
- Libby, P., Theroux, P., 2005. Pathophysiology of Coronary Artery Disease. *Circulation* 111: 3481–3488. doi:10.1161/CIRCULATIONAHA.105.537878
- Loennechen, J.P., Støylen, A., Beisvag, V., Wisløff, U., & Ellingsen, Ø., 2001. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. *Am. J. Physiol. - Hear. Circ. Physiol.* 280: 2902–2910. doi:10.1152/ajpheart.2001.280.6.h2902
- Marasciulo, F., Montagnani, M., Potenza, M., 2006. Endothelin-1: The Yin and Yang on Vascular Function. *Curr. Med. Chem.* 13: 1655–1665. doi:10.2174/092986706777441968
- Mayyas, F., Al-Jarrah, M., Ibrahim, K., Mfady, D., Van Wagoner, D.R., 2015. The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization. *Cardiovasc. Pathol.* 24: 19–25. doi:10.1016/j.carpath.2014.08.004
- Miyauchi, T., Masaki, T., 1999. PATHOPHYSIOLOGY OF ENDOTHELIN IN THE CARDIOVASCULAR SYSTEM. *Annu. Rev. Physiol.* 61: 391–415. doi:10.1146/annurev.physiol.61.1.391
- Nakahara, T., Dweck, M.R., Narula, N., Pisapia, D., Narula, J., Strauss, H.W., 2017. Coronary Artery Calcification. *JACC Cardiovasc. Imaging* 10: 582–593. doi:10.1016/j.jcmg.2017.03.005
- Oemrawsingh, R.M., Akkerhuis, K.M., Van Vark, L.C., Redekop, W.K., Rudez, G., Remme, W.J., Bertrand, M.E., Fox, K.M., Ferrari, R., Danser, A.H.J., de Maat, M., Simoons, M.L., Brugts, J.J., Boersma, E., 2016. Individualized Angiotensin- Converting Enzyme (ACE)- Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. *J. Am.*

- Heart Assoc.* 5. doi:10.1161/JAHA.115.002688
- Patti, G., *et al.*, 2019. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. *Nat. Rev. Cardiol.* 16: 113–130. doi:10.1038/s41569-018-0080-2
- Poudel, I., Tejpal, C., Rashid, H., Jahan, N., 2019. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review. *Cureus.* doi:10.7759/cureus.5280
- Radi B, *et al*, 2016. Pedomani Uji Latih Jantung. *Perhimpun. Dr. Spes. Kardiovask. Indones.* 1–50.
- Ren, A., Wu, H., Liu, L., Guo, Z., Cao, Q., Dai, Q., 2019. Nicotine promotes atherosclerosis development in apolipoprotein E- deficient mice through  $\alpha 1$ -nAChR. *J. Cell. Physiol.* 234: 14507–14518. doi:10.1002/jcp.27728
- Sabatine, M.S., Morrow, D.A., de Lemos, J.A., Omland, T., Sloan, S., Jarolim, P., Solomon, S.D., Pfeffer, M.A., Braunwald, E., 2012. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease. *Circulation* 125: 233–240. doi:10.1161/CIRCULATIONAHA.111.063842
- Salehi, N., Janjani, P., Tadbiri, H., Rozbahani, M., Jalilian, M., 2021. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review. *J. Int. Med. Res.* 49. doi:10.1177/03000605211059893
- Savji, N., Rockman, C.B., Skolnick, A.H., Guo, Y., Adelman, M.A., Riles, T., Berger, J.S., 2013. Association Between Advanced Age and Vascular Disease in Different Arterial Territories. *J. Am. Coll. Cardiol.* 61: 1736–1743. doi:10.1016/j.jacc.2013.01.054
- Schiffirin, E.L., Pollock, D.M., 2024. Endothelin System in Hypertension and Chronic Kidney Disease. *Hypertension* 81: 691–701. doi:10.1161/HYPERTENSIONAHA.123.21716
- Schnabel, R.B., Schulz, A., Messow, C.M., Lubos, E., Wild, P.S., Zeller, T., Sinning, C.R., Rupprecht, H.J., Bickel, C., Peetz, D., Cambien, F., Kempf, T., Wollert, K.C., Benjamin, E.J., Lackner, K.J., Münzel, T.F., Tired, L., Vasan, R.S., Blankenberg, S., 2010. Multiple marker approach to risk stratification in patients with stable coronary artery disease. *Eur. Heart J.* 31: 3024–3031. doi:10.1093/eurheartj/ehq322
- Schwartz, G.G., Steg, P.G., Szarek, M., Bhatt, D.L., Bittner, V.A., Diaz, R., Edelberg, J.M., Goodman, S.G., Hanotin, C., Harrington, R.A., Jukema, J.W., Lecorps, G., Mahaffey, K.W., Moryusef, A., Pordy, R., Quintero, K., Roe, M.T., Sasiela, W.J., Tamby, J.-F., Tricoci, P., White, H.D., Zeiher, A.M., 2018. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N. Engl. J. Med.* 379: 2097–2107. doi:10.1056/NEJMoa1801174
- Soesanto, A.M., Rahimah, A.F., Kuncoro, A.S., 2020. Pedomani Tatalaksana Panduan Pemilihan Modalitas Diagnostik Non Invasif Pada Angina Pectoris Stabil. *Perhimpun. Dr. Spes. Kardiovask. Indones.*
- Stark, B., Johnson, C., Roth, G.A., 2024. Global Prevalence of Coronary Artery Disease: an Update From the Global Burden of Disease Study. *J. Am. Coll.*

*Cardiol.* 83: 2320. doi:10.1016/s0735-1097(24)04310-9

- Tsujimoto, T., Kajio, H., 2020. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension. *J. Am. Heart Assoc.* 9. doi:10.1161/JAHA.120.018827
- Vojáček, J., Kolář, J., Lisý, O., Hraboš, V., Šimek, S., Jindra Jr., A., Jáchymová, M., 1999. Time Course of Endothelin-1 Plasma Level in Patients with Acute Coronary Syndromes. *Cardiology* 91: 114–118. doi:10.1159/000006890
- Vrints, C., *et al.*, 2024. 2024 ESC Guidelines for the management of chronic coronary syndromes. *Eur. Heart J.* 45: 3415–3537. doi:10.1093/eurheartj/ehae177
- Yu, A.P., Tam, B.T., Yau, W.Y., Chan, K.S., Yu, S.S., Chung, T.L., Siu, P.M., 2015. Association of endothelin-1 and matrix metalloproteinase-9 with metabolic syndrome in middle-aged and older adults. *Diabetol. Metab. Syndr.* 7: 111. doi:10.1186/s13098-015-0108-2
- Zhou, B.-Y., Guo, Y.-L., Wu, N.-Q., Zhu, C.-G., Gao, Y., Qing, P., Li, X.-L., Wang, Y., Dong, Q., Liu, G., Xu, R.X., Cui, C.-J., Sun, J., Li, J.-J., 2017. Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. *Int. J. Cardiol.* 230: 76–79. doi:10.1016/j.ijcard.2016.12.082